Acute effects of statin on reduction of angiopoietin-like 2 and glyceraldehyde-derived advanced glycation end-products levels in patients with acute myocardial infarction: a message from SAMIT (Statin for Acute Myocardial Infarction Trial)

作者：Shimomura Mitsuhiro; Oyama Jun ichi^*; Takeuchi Masayoshi; Shibata Yoshisato; Yamamoto Yusuke; Kawasaki Tomohiro; Komoda Hiroshi; Kodama Kazuhisa; Sakuma Masashi; Toyoda Shigeru; Inoue Yohei; Mine Daigo; Natsuaki Masahiro; Komatsu Aiko; Hikichi Yutaka; Yamagishi Sho ichi; Inoue Teruo; Node Koichi

来源：Heart and Vessels, 2016, 31(10): 1583-1589.

DOI：10.1007/s00380-015-0773-y

• Statin
• Acute myocardial infarction
• Inflammation
• Oxidative stress

Experimental ischemia-reperfusion models have shown that 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, statins, have cardioprotective effects. SAMIT (Statin Acute Myocardial Infarction Trial) is a multicenter prospective open randomized trial, designed to evaluate the effects of statin treatment from the earliest stage on cardioprotection in patients with acute myocardial infarction (AMI). Patients were randomly assigned to receive atorvastatin (initial dose of 40 mg at admission followed by the maintenance dose of 10 mg/day for 30 days) or not (control), and then immediately underwent percutaneous coronary intervention (PCI) for the culprit lesion. The primary endpoints were infarct size and left ventricular function. The secondary endpoints were major adverse cardiac and cerebrovascular events (MACCE) and various biomarkers. There were no significant differences in baseline characteristics between 2 groups of the statin treatment group and the control group. The left ventricular ejection fraction increased at 6 months after the onset of AMI, compared with the baseline level in the atorvastatin group (P < 0.05), while it did not change in the control group. Although there were no significant differences in the MACCE, the changes in the levels of angiopoietin-like protein 2 (ANGPTL2) (P < 0.05), and glyceraldehyde-derived advanced glycation end-products, (TAGE) (P < 0.01) were suppressed at 2 weeks in the atorvastatin group, compared with the control group. Statin therapy started early after the onset reduced the levels of ANGPTL2 and TAGE, and thus, might have cardioprotective effects in patients with AMI.

• 出版日期2016-10